XML 87 R67.htm IDEA: XBRL DOCUMENT v3.25.4
License and Acquisition Agreements - Regeneron License Agreement (Details) - USD ($)
$ in Thousands
 1 Months Ended 12 Months Ended
Sep. 30, 2017
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Mar. 31, 2021
License and Acquisition Agreements          
Intangible asset - Regulatory milestone   $ 20,000 $ 20,000    
Research and development   96,853 111,623 $ 76,097  
Commercial product inventory   54,895 26,364    
Regulatory milestone          
License and Acquisition Agreements          
Intangible asset - Regulatory milestone   20,000 20,000    
Regeneron | Regulatory milestone          
License and Acquisition Agreements          
Intangible asset - Regulatory milestone   32,500     $ 20,000
Regeneron | License agreement          
License and Acquisition Agreements          
Profit sharing recognized   229,545 127,375 56,524  
Regeneron | Clinical supply agreement          
License and Acquisition Agreements          
Research and development   0 0 $ 1,356  
Uncured period which causes termination of the agreement, due to insolvency or bankruptcy or for material breach of the agreement by the other party that remains uncured 90 days        
Notice period to terminate the agreement under payment-related breaches 30 days        
Consecutive suspension of activities period for termination of agreement 12 months        
Notice period to terminate the agreement 1 year        
Notice period to terminate the agreement if products are having safety concerns 3 months        
Commercial product inventory   $ 29,071 $ 21,246